Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ryuta Mitani
Observed name:
R. Mitani
Institution:
National Cancer Center Hospital East
Observed institution:
National Cancer Center Hospital East
ORCID:
0009-0007-2132-1232
Observed ORCID:
0009-0007-2132-1232
OpenAlex ID:
A5073000017
Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy
2022
·
Yoshiaki Nakamura
, Wataru Okamoto
, et al.
·
JCO Precision Oncology
·
33
Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy
2023
·
Yu Aoki
, Yoshiaki Nakamura
, et al.
·
JCO Precision Oncology
·
16
PDF
Figure 5 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Data from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Supplementary Table 4 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Supplementary Table 5 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Supplementary Figure 3 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Supplementary Figure 2 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Figure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Supplementary Table 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Supplementary Table 2 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Supplementary Table 3 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Supplementary Figure 4 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Figure 4 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Figure 3 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Figure 2 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Supplementary Figure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
2026
·
Kenjiro Namikawa
, Dai Ogata
, et al.
·
Cancer Research Communications
PDF
775P Melanoma recurrence prediction using a tissue-free epigenomic minimal residual disease assay: A multicenter prospective observational study (COSMOS-MEL01)
2025
·
K. Namikawa
, D. Ogata
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
19
Citation count:
49
H-index:
2
I10-index:
2
Year
Topic
Type